摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(2-chloro-3-methoxyphenyl)pyrimidine-2,4-(1H,3H)-dione | 830346-42-4

中文名称
——
中文别名
——
英文名称
5-(2-chloro-3-methoxyphenyl)pyrimidine-2,4-(1H,3H)-dione
英文别名
5-(2-chloro-3-methoxyphenyl)pyrimidine-2,4(1H,3H)-dione;5-(2-chloro-3-methoxyphenyl)-1H-pyrimidine-2,4-dione
5-(2-chloro-3-methoxyphenyl)pyrimidine-2,4-(1H,3H)-dione化学式
CAS
830346-42-4
化学式
C11H9ClN2O3
mdl
——
分子量
252.657
InChiKey
DMWBZRUWLFZPIC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    67.4
  • 氢给体数:
    2
  • 氢受体数:
    3

SDS

SDS:ea92749cf2cf94dbaba707ac3654cc75
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-(2-chloro-3-methoxyphenyl)pyrimidine-2,4-(1H,3H)-dione2-氟-6-(三氟甲基)溴苄N,O-双三甲硅基乙酰胺 作用下, 以 乙腈 为溶剂, 反应 17.5h, 以88%的产率得到5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)-benzyl]pyrimidine-2,4-(1H,3H)-dione
    参考文献:
    名称:
    [EN] PYRIMIDINE-2, 4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS
    [FR] DERIVES DE PYRIMIDINE-2, 4-DIONE UTILISES COMME ANTAGONISTES DU RECEPTEUR D'HORMONE LIBERANT DE LA GONADOTROPHINE
    摘要:
    GnRH受体拮抗剂被披露,对男性和女性的各种与性激素相关的疾病具有治疗作用。本发明的化合物具有以下结构:其中R1a、R1b、R1c、R2a、R2b、R3、R4、R5、R6和X的定义如本文所述,包括立体异构体、前药和其药用可接受盐。还披露了含有本发明化合物的组合物与药用可接受载体的组合物,以及与在需要时对抗性腺激素释放激素的使用方法。
    公开号:
    WO2005007165A1
  • 作为产物:
    描述:
    ethyl 2-(2-chloro-1-methoxyphenyl)-3-(dimethylamino)acrylate尿素三甲基氯硅烷 、 sodium iodide 、 sodium hydroxide 作用下, 以 乙腈 为溶剂, 反应 36.0h, 以82%的产率得到5-(2-chloro-3-methoxyphenyl)pyrimidine-2,4-(1H,3H)-dione
    参考文献:
    名称:
    [EN] PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS
    [FR] DERIVES DE PYRIMIDINE-2,4-DIONE, SERVANT D'ANTAGONISTES AU RECEPTEUR DE L'HORMONE DE LIBERATION DE LA GONADOTROPINE
    摘要:
    GnRH受体拮抗剂已被披露,可用于治疗男性和女性的各种与性激素相关的疾病。本发明的化合物具有结构式(I),其中R1a、R1b、R2a、R2b、R3、R4、R5、R6、R7和X如本文所定义,包括立体异构体、前药和其药用盐。此外,还披露了含有本发明化合物的组合物,该组合物与药用载体结合,以及涉及使用该组合物来拮抗需要此类治疗的受试者的促性腺激素释放激素的方法。
    公开号:
    WO2005007164A1
点击查看最新优质反应信息

文献信息

  • [EN] GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO<br/>[FR] ANTAGONISTES DES RECEPTEURS DES HORMONES LIBERANT DES GONADOTROPINES ET PROCEDES CONNEXES
    申请人:NEUROCRINE BIOSCIENCES INC
    公开号:WO2005007633A1
    公开(公告)日:2005-01-27
    GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein n, R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    抑制性激素释放激素受体拮抗剂已经被披露,可用于治疗男性和女性的多种与性激素相关的疾病。本发明的化合物具有以下结构:其中n、R1a、R1b、R1c、R2a、R2b、R3、R4、R5、R6和X如本文所定义,包括立体异构体、前药和其药用可接受的盐。还披露了含有本发明化合物的组合物,以及与药用可接受载体结合的方法,用于拮抗需要的受试者体内的促性腺激素释放激素。
  • Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
    申请人:Guo Zhiqiang
    公开号:US20050038057A1
    公开(公告)日:2005-02-17
    GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R 1a , R 1b , R 1c , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    本发明揭示了GnRH受体拮抗剂,可用于治疗男女性激素相关疾病的多种情况。本发明的化合物具有以下结构:其中R1a,R1b,R1c,R2a,R2b,R3,R4,R5,R6和X的定义如本文所述,包括立体异构体,前药和其药物可接受的盐。还揭示了含有本发明化合物的组合物及其与药物可接受的载体的组合物,以及与用于拮抗需要该类物质的受试者的促性腺激素释放激素相关的方法。
  • GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
    申请人:Guo Zhiqiang
    公开号:US20070191403A1
    公开(公告)日:2007-08-16
    GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R 1a , R 1b , R 1c , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    本发明公开了具有治疗男女性激素相关疾病的效用的GnRH受体拮抗剂。本发明的化合物具有以下结构:其中,R1a、R1b、R1c、R2a、R2b、R3、R4、R5、R6和X的定义如本文所述,包括立体异构体、前药和其药物可接受的盐。本发明还公开了含有本发明化合物与药物可接受载体结合的组合物,以及与拮抗需要拮抗性腺激素释放激素的受试者相关的使用方法。
  • Gonadotropin-releasing hormone receptor antagonists and methods related thereto
    申请人:Neurocrine Biosciences, Inc.
    公开号:US07419983B2
    公开(公告)日:2008-09-02
    GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    本发明公开了GnRH受体拮抗剂,其在治疗男女性激素相关疾病方面具有实用性。本发明化合物具有以下结构:其中R1a、R1b、R1c、R2a、R2b、R3、R4、R5、R6和X的定义如本文所述,包括立体异构体、前药和其药学上可接受的盐。本发明还公开了含有该化合物与药学上可接受的载体组合的组合物,以及与拮抗性促性腺激素释放激素有关的使用方法,用于需要该方法的受体。
  • Arylpyrimidines useful for the treatment of sex hormone-related conditions such as endometriosis, prostate cancer and the like
    申请人:NEUROCRINE BIOSCIENCES, INC.
    公开号:EP1644342B1
    公开(公告)日:2012-05-09
查看更多